EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm

Milad Soltanzadeh, Zheng Wang, Shona G Allohverdi, Colleen E Charlton, André Schmidt, Franz X Vollenweider, Andreea O Diaconescu

Psychopharmacology · 2026-09 · 243 (9) · 2069-2083

DOI: 10.1007/s00213-025-06952-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology, online erschienen am 05.11.2025. Verfasst von Milad Soltanzadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada. milad.soltanzadeh@mail.utoronto.ca. Hauptthemen laut MEDLINE: Ketamine, Psilocybin, Electroencephalography, Hallucinogens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Canadian Institute for Health Research (CIHR), Swiss Neuromatrix Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Ketamine and psilocybin have demonstrated therapeutic potential for mental disorders, including major depressive disorder, yet they engage distinct mechanisms of action. Ketamine, a dissociative hallucinogen, acts by blocking N-methyl-D-aspartate receptors (NMDAR), whereas psilocybin primarily targets serotonin receptors. These divergent mechanisms are reflected in their electrophysiological biomarkers. OBJECTIVES: This study aimed to investigate the divergent effects of ketamine and psilocybin on different elements of the EEG frequency spectrum, focusing on aperiodic components as an indicator of excitation-inhibition balance in the neural circuitry. METHODS: We re-analyzed a previously acquired EEG dataset from healthy volunteers using a placebo-controlled within-subject crossover design (Schmidt et al., Neuropsychopharmacology 37(4):865-875 2012). Participants received either placebo or S-ketamine (N=19) and placebo or psilocybin (N=16) during an auditory roving paradigm. Spectral parameters including periodic and aperiodic were extracted and partial least squares analysis was employed. RESULTS: Ketamine significantly altered the offset and slope of the EEG spectrum, suggesting a disruption in excitatory-inhibitory balance. While both drugs commonly reduced alpha power in similar regions, beta band activity was decreased exclusively under ketamine. CONCLUSIONS: These findings highlight ketamine's unique effects on aperiodic EEG components, reinforcing its role as a neurochemical model of prodromal psychosis. Psilocybin's effects appear distinct, emphasizing its targeted influence on oscillatory activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetaminePsilocybinElectroencephalographyHallucinogensHumansCross-Over StudiesMaleAdultFemaleYoung AdultDouble-Blind Method

Stichwörter der Autor:innen

1/fAperiodic componentEEGKetaminePartial least squaresPsilocybinPsychedelics

Substanzen

KetaminePsilocybinHallucinogens

Autor:innen und Institutionen

  • Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada. milad.soltanzadeh@mail.utoronto.ca.
  • Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, M5T 1R8, ON, Canada. milad.soltanzadeh@mail.utoronto.ca.
  • Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, M5T 1R8, ON, Canada.
  • Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada.
  • Department of Clinical Research (DKF), University of Psychiatric Clinics (UPK), University of Basel, Wilhelm Klein-Strasse 27, Basel, 4002, Switzerland.
  • Neuropsychopharmacology and Brain Imaging Unit, University Hospital of Psychiatry, Lenggstrasse 31, Zurich, 8008, Switzerland.

Förderung

  • Canadian Institute for Health Research (CIHR)
  • Swiss Neuromatrix Foundation

Zitieren

APA

Soltanzadeh, M., Wang, Z., Allohverdi, S. G., Charlton, C. E., Schmidt, A., Vollenweider, F. X., & Diaconescu, A. O. (2026). Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm. Psychopharmacology, 243(9), 2069-2083. https://doi.org/10.1007/s00213-025-06952-2

Vancouver

Soltanzadeh M, Wang Z, Allohverdi SG, Charlton CE, Schmidt A, Vollenweider FX, et al. Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm. Psychopharmacology. 2026;243(9):2069-2083. doi:10.1007/s00213-025-06952-2

BibTeX
@article{Soltanzadeh2026,
  author = {Soltanzadeh, Milad and Wang, Zheng and Allohverdi, Shona G and Charlton, Colleen E and Schmidt, André and Vollenweider, Franz X and Diaconescu, Andreea O},
  title = {Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm},
  journal = {Psychopharmacology},
  year = {2026},
  volume = {243},
  number = {9},
  pages = {2069--2083},
  doi = {10.1007/s00213-025-06952-2}
}
Kostenlos starten →